Fate Therapeutics, Inc. (FATE) Shareholder Notice: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Class Action Against Fate Therapeutics, Inc.

SAN DIEGO--(BUSINESS WIRE)---- $FATE #FATE--Fate Therapeutics, Inc. (FATE) Misrepresented the Impact of the Janssen Collaboration Agreement on its Long-Term Clinical and Commercial Profitability